CLINICAL EVALUATION OF RADIOTHERAPY FOR N0 HYPOPHARYNGEAL CANCER

Seventy-five hypopharyngeal cancer patients without lymph-node metastasis, treated with radiotherapy at Kyushu University Hospital from 1976 through 2003, were evaluated. T category was 10 in T1, 41 in T2, 13 in T3, and 11 in T4. Median total doses of radiation therapy were 62.5Gy (range : 60-74Gy) in radical intent, and 30Gy (28.5-41.4Gy) in the preoperative setting. Patient selection as to radical radiotherapy or preoperative irradiation plus surgery was performed at 30-40Gy by an oncologist of head and neck surgery and a radiation oncologist, according to the tumor response to radiation therapy. Most patients were treated with radiotherapy combined with concurrent chemotherapy including 5-fluorouracil (5-FU) and Vitamin A. As the result, radical radiotherapy was selected for 48 patients (T1, 9 ; T2, 30 ; T3, 4 ; T4, 5), and preoperative irradiation plus surgery was selected for 27 patients (T1, 1 ; T2, 11 ; T3, 9 ; T4, 6) For 75 T1-4 cancer patients, the 5-year overall and cause-specific survival rates were 62% and 75%, respectively. The 5-year cause-specific survival (5y-CSS) rates were 100% for T1, 85% for T2, 83% for T3, and 30% for T4. For patients with T1-2 cancers, there was no significant difference in survival between the RT+Surgery group and the RT group ; 5-year CSS was 92% vs. 85%, respectively. In the RT group, however, the prognosis of patients with T3-4 cancers (5-year CSS : 29%) was significantly poor compared with that of patients with T1-2 cancers. The 5-year local progression-free survival with laryngeal preservation was 65% in T1-2 cancers, 6% in T3-4 cancers, and 45% in all patients. Radiotherapy has an advantage for the preservation of laryngeal function compared with surgery. For stage I-II cancers, therefore, radiotherapy should be first considered as a radical treatment option. For T3-4 cancers, however, the combination of radiotherapy and surgery was thought to be proper treatment.